Table 1 Baseline characteristics of the study population
Variables | 0VD (N = 988) | DA (N = 302) | 1VD (N = 3295) | 2VD (N = 2114) | 3VD (N2190) | P values |
|---|---|---|---|---|---|---|
Age (years) | 62 {53, 72} | 66 {56, 74} | 63 {54, 71} | 67 {59, 75} | 71 {63, 78} | < 0.001 |
Female gender | 585 (59.9) | 131 (44.0) | 966 (29.6) | 489 (23.3) | 587 (27.0) | < 0.001 |
Hypertension | 368 (39.2) | 143 (49.7) | 1290 (41.6) | 875 (44.4) | 1088 (53.6) | < 0.001 |
Hyperlipidemia | 427 (45.5) | 144 (49.5) | 1517 (48.9) | 1060 (53.6) | 1093 (53.9) | < 0.001 |
Diabetes mellitus | 106 (11.0) | 51 (17.2) | 413 (12.9) | 342 (16.6) | 488 (23.0) | < 0.001 |
IHD in the family | 347 (37.4) | 113 (40.1) | 1231 (40.5) | 765 (39.3) | 750 (37.9) | 0.3072 |
Current smoker | 293 (32.4) | 100 (36.6) | 1303 (42.7) | 772 (39.4) | 654 (33.0) | < 0.001 |
Overweighta | 463 (57.7) | 143 (55.6) | 1764 (67.3) | 1097 (66.7) | 1059 (64.4) | < 0.001 |
Renal insufficiencyb | 107 (13.8) | 39 (15.4) | 353 (13.8) | 310 (19.0) | 457 (28.0) | < 0.001 |
EF < 50% | 107 (22.1) | 37 (25.2) | 282 (19.5) | 258 (28.7) | 427 (42.3) | < 0.001 |
Previous stroke | 36 (3.6) | 15 (5.0) | 113 (3.4) | 111 (5.3) | 189 (8.6) | < 0.001 |
Treatment | ||||||
Any revascularisationc | 26 (2.6) | 15 (5.0) | 2764 (83.9) | 1816 (85.9) | 1688 (77.1) | < 0.001 |
PCI | 21 (2.1) | 11 (3.7) | 2728 (82.8) | 1588 (75.1) | 769 (35.1) | < 0.001 |
CABG | 5 (0.5) | 4 (1.3) | 36 (1.1) | 228 (10.8) | 919 (42.0) | < 0.001 |
Aspirin | 883 (90.9) | 288 (95.7) | 3177 (96.6) | 2039 (96.5) | 2048 (93.8) | <0.001 |
P2Y12 receptor inhibitor | 668 (67.7) | 235 (78.1) | 3097 (94.2) | 1920 (90.9) | 1642 (75.2) | <0.001 |
Beta blocker | 758 (78.1) | 263 (87.4) | 2964 (90.1) | 1892 (89.6) | 1975 (90.5) | <0.001 |
ACE-inhibitor | 428 (44.1) | 147 (48.8) | 1641 (49.9) | 1175 (55.6) | 1363 (62.4) | <0.001 |
Statin | 808 (83.2) | 277 (92.0) | 3103 (94.3) | 1968 (93.2) | 1978 (90.6) | <0.001 |